Greenwich LifeSciences Q1 Net Loss Doubles to $5.66M, Zero Revenue Persists
Summary
Greenwich LifeSciences reported Q1 2026 results with $0 revenue, a net loss of $(5.66M), and diluted EPS of $(0.39). This represents a significant widening of the net loss from $(2.74M) in Q1 2025. This follows the 10-Q filed on June 3rd, which already indicated a substantial increase in Q1 net losses and cash burn, and reiterated a going concern warning. The doubling of net losses year-over-year, coupled with zero revenue, highlights the company's significant cash burn as it advances its clinical programs. This is particularly critical given the recent going concern warnings and internal control weaknesses disclosed in earlier filings. The company is prioritizing enrollment for its FLAMINGO-01 trial, which will be key to its regulatory pathway.
At the time of this announcement, GLSI was trading at $23.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $356.5M. The 52-week trading range was $7.78 to $34.10. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.